---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-031185"
form_type: "8-K"
ticker: null
cik: "0001042074"
company_name: "CymaBay Therapeutics, Inc."
filed_at: "2024-02-12T23:59:59+00:00"
generated_at: "2026-06-06T04:07:16.302987+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Gilead to acquire CymaBay for $32.50/sh ($4.3B); seladelpar PBC drug with priority review

## Summary
- All-cash tender at $32.50/share, a 27% premium to Feb. 9 close; equity value ~$4.3B.
- Seladelpar (PPARδ agonist) for primary biliary cholangitis has FDA priority review; PDUFA Aug. 14, 2024.
- Phase 3 RESPONSE trial: 61.7% biochemical response vs 20% placebo; 25% ALP normalization vs 0%.
- Closing expected Q1 2024, subject to HSR and minimum tender of majority of shares.
- Termination fee of $151.6M payable by CymaBay under certain circumstances.

## SEC filing metadata
- accession: 0001193125-24-031185
- form_type: 8-K
- cik: 0001042074
- company_name: CymaBay Therapeutics, Inc.
- filed_at: 2024-02-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1042074/000119312524031185/0001193125-24-031185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1042074/000119312524031185/d791540d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-031185
- JSON: https://secwatch.observer/filing/0001193125-24-031185.json
- Plain text: https://secwatch.observer/filing/0001193125-24-031185.txt

## Key facts
- Governance Changes
  CymaBay Therapeutics, Inc.: Added new Article XV to Bylaws establishing exclusive forum provisions for certain legal actions, including federal district courts for Securities Act and Exchange Act claims (effective 2024-02-11).
  - Change: bylaw amendment
  - Effective: 2024-02-11
  source text: On February 11, 2024, the Board adopted an amendment (the “ Amendment ”) to the Company’s bylaws (as may be amended from time to time, the “ Bylaws ”), which became effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1042074/000119312524031185/0001193125-24-031185-index.htm
- Material Agreements
  CymaBay Therapeutics, Inc. entered into Agreement and Plan of Merger with Gilead Sciences, Inc. (effective 2024-02-11).
  - Action: entry
  - Agreement: merger
  - Counterparty: Gilead Sciences, Inc.
  - Effective: 2024-02-11
  source text: On February 11, 2024, CymaBay Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Gilead Sciences, Inc., a Delaware corporation (“ Parent ”), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1042074/000119312524031185/0001193125-24-031185-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.